Insys Therapeutics (NASDAQ:INSY) was downgraded by equities research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Thursday.
Other equities research analysts also recently issued reports about the stock. Oppenheimer reissued a “hold” rating on shares of Insys Therapeutics in a research note on Sunday, November 12th. Zacks Investment Research downgraded shares of Insys Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 22nd. Finally, Jefferies Group reduced their price target on shares of Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. Insys Therapeutics presently has a consensus rating of “Hold” and an average target price of $9.38.
Insys Therapeutics (NASDAQ INSY) traded up $0.02 during trading on Thursday, hitting $7.31. 418,481 shares of the stock were exchanged, compared to its average volume of 969,984. The stock has a market cap of $535.94, a P/E ratio of -2.87 and a beta of 0.78. Insys Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.02.
TRADEMARK VIOLATION WARNING: This article was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3231919/insys-therapeutics-insy-rating-lowered-to-strong-sell-at-valuengine.html.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.